Antiproliferative Factor Glycopeptide for Interstitial Cystitis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating interstitial cystitis are inadequate, as the pathogenesis is unknown, and existing treatments do not effectively address the underlying cellular proliferation issues contributing to the condition.
Innovation Solution
Development of an antiproliferative factor (APF) compound, a glycopeptide that inhibits cell proliferation, which can be used as a biomarker for interstitial cystitis and as a therapeutic agent to treat the condition by regulating cell adhesion and growth factor production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic methods are used for interstitial cystitis, then the diagnosis can be made, but the pathogenesis remains unknown and treatment effectiveness is limited
Solution Approach 1:
The patent extracts and identifies a specific biomarker (antiproliferative factor or APF) from the complex urinary environment of interstitial cystitis patients. This biomarker is isolated and characterized to serve as a diagnostic tool, while its identification also provides insight into the underlying pathogenesis by revealing the cellular mechanisms involved in the disease.
Solution Approach 2:
The patent introduces APF as an intermediary substance that mediates between the unknown pathogenesis and the diagnostic process. By detecting APF in urine, the patent creates a measurable link that both diagnoses the condition and elucidates the underlying cellular proliferation issues without requiring direct observation of the disease mechanism.
2Ease of operation
If existing treatments are used for interstitial cystitis, then the condition can be managed, but the underlying cellular proliferation issues are not effectively addressed
Solution Approach 1:
The patent converts the harmful effect of uncontrolled cellular proliferation into a beneficial diagnostic and therapeutic target. By identifying APF as the mediator of this harmful process, the patent enables treatments that specifically target and correct the underlying proliferation issue, transforming a previously unmanageable cellular dysfunction into a treatable condition.
Solution Approach 2:
The patent changes the therapeutic parameter from general symptom management to specific molecular targeting. By focusing treatment on the APF pathway and cellular proliferation mechanisms, the patent achieves more reliable treatment effectiveness while maintaining ease of operation through defined therapeutic protocols.
3Measurement precision
If APF is used as a biomarker, then specific diagnosis of interstitial cystitis is achieved, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent extracts APF as a specific, identifiable biomarker from the complex urinary matrix. By isolating and characterizing this single specific molecule, the patent achieves high measurement precision for diagnosing interstitial cystitis without requiring complex multi-parameter analysis systems.
Solution Approach 2:
The patent makes APF serve multiple functions: it acts as both a diagnostic biomarker and a therapeutic target. This multi-functionality reduces the need for separate diagnostic and therapeutic processes, thereby reducing overall system complexity while maintaining high specificity for the disease.
4Reliability
If APF is used as a therapeutic agent, then the underlying pathogenesis is addressed, but the development and application complexity increases
Solution Approach 1:
The patent converts the harmful cellular proliferation process into a beneficial therapeutic target. By identifying APF as the specific mediator of this harmful process, the patent enables targeted therapies that address the root cause rather than symptoms, improving reliability while managing development complexity through focused research areas.
Solution Approach 2:
The patent changes the therapeutic approach from non-specific to specific molecular targeting. By focusing on the APF pathway and its role in cellular proliferation, the patent achieves reliable pathogenesis targeting while managing development complexity through defined molecular mechanisms and clear therapeutic objectives.
Data Source
AI summary
A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.